.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Fuji
Merck
Healthtrust
Julphar
Dow
Farmers Insurance
Queensland Health
Federal Trade Commission
Cipla

Generated: September 23, 2017

DrugPatentWatch Database Preview

Troglitazone - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for troglitazone and what is the scope of troglitazone freedom to operate?

Troglitazone
is the generic ingredient in two branded drugs marketed by Sankyo and Pfizer Pharms, and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Troglitazone has forty-five patent family members in thirty-six countries.

Summary for Generic Name: troglitazone

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Bulk Api Vendors: see list52
Clinical Trials: see list16
Patent Applications: see list7,679
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:troglitazone at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: troglitazone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-002Jan 29, 1997► Subscribe► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-002Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-001Jan 29, 1997► Subscribe► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-001Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-003Aug 4, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997► Subscribe► Subscribe
Pfizer Pharms
REZULIN
troglitazone
TABLET;ORAL020720-002Jan 29, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: troglitazone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,972,973 Sulfonylurea-glitazone combinations for diabetes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: troglitazone

Country Document Number Estimated Expiration
European Patent Office0957923► Subscribe
Estonia9900345► Subscribe
Argentina020973► Subscribe
Honduras1999000184► Subscribe
Norway993982► Subscribe
World Intellectual Property Organization (WIPO)9836755► Subscribe
Panama8447401► Subscribe
South Korea20000071179► Subscribe
Australia5590898► Subscribe
Australia741215► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TROGLITAZONE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/084United Kingdom► SubscribePRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Accenture
Novartis
Deloitte
QuintilesIMS
Dow
Julphar
Fuji
Covington
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot